Research in Social and Administrative Pharmacy
Volume 1, Issue 1 , Pages 77-100 , March 2005

Patients' willingness to pay for pharmacist-provided menopause and hormone replacement therapy consultations⋆

References 

  1. Sulak PJ. The perimenopause: a critical time in a woman's life. Int J Fertil Menopausal Stud. 1996;41:85–89
  2. Shepherd JE. Effects of estrogen on cognition, mood, and degenerative brain diseases. J Am Pharm Assoc. 2001;41:221–228
  3. Archer DF, Gass MS, Gelfand MM, et al. Clinical challenges of perimenopause: consensus opinion of the North American Menopause Society. Menopause. 2000;7:5–12
  4. Whitehead MI. General principles of administration of hormone replacement therapy: indications and contraindications, routes of administration, treatment schedules. In:  Fraser IS,  Jansen RPS,  Lobo RA, et al. editor. Estrogens and Progestogens in Clinical Practice. 1st ed.. Edinburgh: Harcourt Publishers Ltd; 2000;p. 667–686
  5. Clinical Synthesis Panel on HRT . Clinical synthesis conference: hormone replacement therapy. Lancet. 1999;354:152–155
  6. Gibaldi M. Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy?. J Clin Pharmacol. 1997;37:1087–1099
  7. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  8. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med. 1992;117:1016–1037
  9. Chow MS. Benefit/risk of estrogen therapy in cardiovascular disease: current knowledge and future challenges. J Clin Pharmacol. 1995;35(suppl):11S–17S
  10. Stumpf PG, Trolice MP. Compliance problems with hormone replacement therapy. Obstet Gynecol Clin North Am. 1994;21:219–226
  11. Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol. 1992;99:325–328
  12. Torgerson DJ, Donaldson C, Russell IT, et al. Hormone replacement therapy: compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol. 1995;59:57–60
  13. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center. Maturitas. 1995;20:91–99
  14. Schiff I, Rebar RW, Cramer JA, et al. Achieving long-term continuance of menopausal ERT/HRT: consensus opinion of the North American Menopause Society. Menopause. 1995;5:69–76
  15. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332–1334
  16. Ferguson KJ, Hoegh C, Johnson S. Estrogen replacement therapy: a survey of women's knowledge and attitudes. Arch Int Med. 1989;149:133–136
  17. Nachtigall LE. Enhancing patient compliance with hormonal replacement therapy at menopause. Obstet Gynecol. 1990;75:S77–S80
  18. Conboy L, Domar A, O'Connell E. Women at mid-life: symptoms, attitudes, and choices, and internet based survey. Maturitas. 2001;38:129–136
  19. Kaufert P, Boggs P, Etinger B, et al. Women and menopause: beliefs, attitudes and behaviors. The North American Menopause Society 1997 menopause survey. Menopause. 1998;5(4):197–202
  20. Connelly MT, Ferrari N, Hagen N, et al. Patient-identified needs for hormone replacement therapy counseling: a qualitative study. Ann Intern Med. 1999;131:265–268
  21. American Pharmaceutical Asssociation . APhA national survey: willingness of consumers to pay for pharmacists' clinical services. Am Pharm. 1983;NS23:314–327
  22. Larson R. Patients' willingness to pay for pharmaceutical care. J Am Pharm Assoc. 2000;40:618–624
  23. Suh DC. Consumers' willingness to pay for pharmacy services that reduce risk of medication-related problems. J Am Pharm Assoc. 2000;40:818–826
  24. Gore PR, Madhavan S. Consumers' preference and willingness to pay for pharmacist counseling of non-prescription medicines. J Clin Pharm Ther. 1994;19:17–25
  25. Reutzel TJ, Furmaga E. Willingness to pay for pharmacist services in a veterans administration hospital. J Res Pharm Econ. 1993;5:89–114
  26. Einarson TR, Bootman JL, Larson LN, et al. Blood level testing in a community pharmacy: consumer demand and financial feasibility. Am Pharm. 1988;NS28:76–79
  27. Barner JC. Patient willingness to pay for diabetes disease state management programs. J Manag Pharm Care. 2001;1:85–96
  28. Barner JC, Mason HL, Murray MD. Assessment of asthma patients' willingness to pay for and willingness to give time to an asthma self-management program. Clin Ther. 1999;21:878–894
  29. Blumenschein K, Johannesson M. Use of contingent valuation to place a monetary value on pharmacy services: an overview and review of the literature. Clin Ther. 1999;21:1402–1417
  30. Johannesson M, Jonsson B. Willingness to pay for antihypertensive therapy—results of a Swedish pilot study. J Health Econ. 1991;10:461–474
  31. Johannesson M, Johansson PO. Willingness to pay for antihypertensive therapy—further results. J Health Econ. 1993;12:95–108
  32. Ramsey S, Sullivan S, Psaty B, Patrick D. Willingness to pay for antihypertensive care: evidence from a staff-model HMO. Soc Sci Med. 1997;44:1911–1917
  33. Ryan M, Ratcliffe J, Tucker J. Using willingness to pay to value alternative models of antenatal care. Soc Sci Med. 1997;44:371–380
  34. Nunnally JC. Psychometric Theory. New York, NY: McGraw-Hill Book Company; 1978;
  35. Kuntz R, Remmert R. A new trend in pharmacy practice: private consultations. Int J Pharm Compound. 2000;5:170–172
  36. Nau DP, Reid LD, Lipowski EE, et al. Patients' perceptions of the benefits of pharmaceutical care. J Am Pharm Assoc. 2000;40:36–40
  37. Cerulli J. Patients' perceptions of independent community pharmacists. J Am Pharm Assoc. 2002;42:279–282
  38. Johannesson M, Johansson PO, Kristrom B, et al. Willingness to pay for lipid lowering: a health production function approach. Appl Econ. 1993;25:1023–1031
  39. Neumann PJ, Johannesson M. The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care. 1994;32:686–699
  40. North American Menopause Society. The Menopause Core Curriculum Study Guide. October 2002, Section A. Available at: http://www.menopause.org/NR/rdonlyres/9E4D788A-5DD6-4FDB-8D02-2293F7760D7C/0/sga.pdf. Accessed on November 9, 2004.
  41. U.S. National Oceanic and Atmospheric Administration . Report of the NOAA panel on contingent valuation. Fed Regist. 1993;58:4602–4614
  42. Blumenschein K, Johannesson M, Blomquist GC, et al. Experimental results on expressed certainty and hypothetical bias in contingent valuation. South Econ J. 1998;65:169–177

PII: S1551-7411(04)00009-9

doi: 10.1016/j.sapharm.2004.12.008

Research in Social and Administrative Pharmacy
Volume 1, Issue 1 , Pages 77-100 , March 2005

Article Tools

* Image Usage & Resolution